

## Joint Research Management Office (JRMO) Research Protocol for Research Studies

<b>Full Title</b>	GlucovITAL – randomised trial of Volatile vs Total intravenous Anaesthetic for major non-cardiac surgery
<b>Short Title</b>	GlucovITAL
<b>Sponsor</b>	Queen Mary University of London
<b>Contact person</b>	Dr Mays Jawad Research Governance Operations Manager Joint Research Management Office Dept W, Research Services 61 Mile End Road London, E1 4UJ Phone: +44 (0)20 7882 7275/6574 Email: research.governance@qmul.ac.uk
<b>IRAS Number</b>	324653
<b>Sponsor (EDGE) Number</b>	157967
<b>REC Reference</b>	23/PR/0677
<b>Chief Investigators</b>	Professor Gareth Ackland Adult Critical Care Unit Queen Mary University of London/ Barts Health NHSTrust Whitechapel London E1 1FR Phone: +44 (0)20 3594 0351 Email: g.ackland@qmul.ac.uk

**List of sites**

- (1) Dr Gareth Ackland  
Barts Health NHS Trust  
London E1 1FR  
Email: [g.ackland@qmul.ac.uk](mailto:g.ackland@qmul.ac.uk)
- (2) Dr Shaman Jhanji  
The Royal Marsden NHS Foundation  
London SW3 6JJ  
Email: [shaman.jhanji@rmh.nhs.uk](mailto:shaman.jhanji@rmh.nhs.uk)
- (3) Dr Joyce Yeung  
University Hospitals Birmingham Foundations Trust  
Birmingham B9 5SS  
Email: [j.yeung.4@warwick.ac.uk](mailto:j.yeung.4@warwick.ac.uk)
- (4) Professor Benjamin Shelley  
Golden Jubilee Hospital  
Clydebank G81 4HX  
Email: [benjamin.shelley@glasgow.ac.uk](mailto:benjamin.shelley@glasgow.ac.uk)
- (5) Dr Ashok Sundar  
Croydon Health Services NHS Trust  
530 London Road CR7 7YE  
Email: [sundar.ashok@nhs.net](mailto:sundar.ashok@nhs.net)
- (6) Dr Richard Ramsaran  
Liverpool University Trust Hospital  
Prescot street Liverpool L7 8XP  
Email: [richard.ramsaran@liverpoolft.nhs.uk](mailto:richard.ramsaran@liverpoolft.nhs.uk)
- (7) Dr Marcela Vizcaychipi  
Chelsea and Westminster Hospital NHS Foundation Trust  
369 Fulham Road, London, SW10 9NH  
Email: [marcela.vizcaychipi@nhs.net](mailto:marcela.vizcaychipi@nhs.net)

- (8) Dr Caroline Thomas  
Leeds Teaching Hospitals NHS Trust  
Beckett Street, Leeds LS9 7TF  
Email: [caroline.thomas27@nhs.net](mailto:caroline.thomas27@nhs.net)

**List of laboratories**

- (1) The Doctors Laboratory  
1 Mabledone Pl  
London  
WC1H 9AX
- (2) William Harvey Research Institute  
John Vane Science Centre  
Charterhouse Square  
London  
EC1M 6BQ

## Contents

Contents.....	4
1. Glossary.....	5
2. Signature Page .....	6
3. Summary and Synopsis .....	7
4. Introduction .....	8
5. Study Objectives .....	10
6. Study Design.....	12
7. Study Procedures.....	12
8. Laboratories and samples .....	18
9. Safety reporting.....	19
10. Statistical considerations .....	20
11. Ethics .....	23
12. Public Involvement .....	24
13. Data Handling and Record Keeping .....	24
14. Trial Management & Committees .....	26
15. Finance and Funding.....	26
16. Sponsorship and Insurance.....	26
17. Dissemination of Research Findings.....	27
18. References.....	29
19. Appendices .....	31

## 1. Glossary

CI	Chief Investigator
eCRF	Electronic Case Report Form
GCP	Good Clinical Practice
HRA	Health Research Authority
IRAS	Integrated Research Application System
ISF	Investigator Site File
Participant	An individual who takes part in a clinical study
PI	Principal Investigator
QMUL	Queen Mary University of London
REC	Research Ethics Committee
TMF	Trial Master File

## 2. Signature Page

### **CI Agreement**

The study, as detailed within this Research Protocol, will be conducted in accordance with the principles of GCP, the UK Policy Framework for Health and Social Care Research, and the Declaration of Helsinki and any other applicable regulations. I delegate responsibility for the statistical analysis and oversight to a qualified statistician (see declaration below).

**CI name: Professor Gareth Ackland**

**Date:** Gareth Ackland  
Digitally signed by  
Gareth Ackland  
Date: 2024.06.13  
16:28:27 +01'00'

### **Statistician's Agreement**

The study as detailed within this research protocol will be conducted in accordance with the current UK Policy Framework for Health and Social Care Research, the World Medical Association Declaration of Helsinki (1996), principles of ICH E6-GCP, ICH E9 - Statistical principles for Clinical Trials and ICH E10 - Choice of Control Groups. I take responsibility for ensuring the statistical work in this protocol is accurate, and I take responsibility for statistical analysis and oversight in this study.

**Statistician's name: Dr Louise Hiller**

**Signature:** Louise  
**Date:** Hiller  
Digitally signed by  
Louise Hiller  
Date: 2024.06.18  
08:43:52 +01'00'

### 3. Summary and Synopsis

Short title	GlucovITAL
Methodology	National, multi-centre randomised trial
Objectives	<ol style="list-style-type: none"> <li>1. Measuring intraoperative glucose levels</li> <li>2. Examine whether total intravenous anaesthesia (TIVA) reduces postoperative complications (myocardial injury and/or infections) by limiting hyperglycaemia after major noncardiac surgery</li> <li>3. Detecting the individual's risk of developing injurious perioperative hyperglycaemia</li> </ol>
Number of participants	450 participants
Eligibility criteria	Patients aged 50 years and over undergoing elective major noncardiac surgery under general anaesthesia
Statistical methodology and analysis	For the primary outcome of intraoperative blood glucose
Study duration	24 months

## 4. Introduction

### 4.1. Background

The frequent development of high blood glucose levels (stress hyperglycaemia) early during major surgery<sup>1</sup> is consistently and dose-dependently associated with myocardial injury<sup>2</sup> and infections<sup>3</sup>, both of which prolong hospitalisation and accelerate mortality even after discharge from hospital<sup>4</sup>. The majority of individuals who experience complications after surgery associated with hyperglycaemia do not have diabetes mellitus<sup>5</sup>. Hyperglycaemia, which occurs in part through the development of insulin resistance<sup>1</sup>, exacerbates systemic inflammation through acute oxidative stress, leading to organ injury<sup>6</sup>. The risk of sustaining myocardial injury and infections doubles with hyperglycaemia, yet routine detection of injurious levels of hyperglycaemia is not a routine feature of current practice<sup>5</sup>. Moreover, anaesthetic techniques that limit stress hyperglycaemia are unexplored, despite substantial mechanistic differences between intravenous and inhalational anaesthetic agents that alter the risk of disrupting normal glucose control<sup>1</sup>.

The surgical backlog presents a huge challenge to not only increase surgical throughput, but also ensure complications after noncardiac surgery are minimised<sup>7</sup>. At least 50% of individuals develop high blood glucose levels (hyperglycaemia) after tissue injury/trauma<sup>8</sup>, which are associated with, and mechanistically linked to, organ injury and infections after surgery. Numerous mechanisms are likely to contribute to perioperative hyperglycaemia, characterized by a state of insulin resistance - a state of decreased biological response to insulin. Many individuals without diabetes mellitus have established insulin resistance before surgery, a key component of metabolic syndrome which is present in ~25% of the UK population<sup>9</sup>. Mitochondrial bioenergetics controls insulin sensitivity by regulating the cellular redox environment<sup>10</sup>, with impaired mitochondrial electron transport and fatty acid oxidation evident in insulin resistance across diverse tissues<sup>11</sup>. Acquired mitochondrial and glycolytic dysfunction occurs in circulating lymphocytes after surgery, as quantified by ex- vivo respirometry<sup>12</sup>, leading to impaired functionality<sup>13</sup> and cell death<sup>12</sup>. Acute loss of adaptive immune cells results in the failure to temper the inflammatory response generated by the initial innate response to tissue injury<sup>14</sup>. Reduced numbers of T-cells exacerbate systemic inflammation<sup>14, 15</sup> and increases the risk of infection<sup>16</sup> and organ injury<sup>17</sup>, including after surgery<sup>18</sup>.

Despite these startling links and potentially treatable perioperative abnormalities, routine detection of perioperative hyperglycaemia is not a routine feature of current practice in individuals without diabetes mellitus, unless they are admitted to a high-dependency/critical care unit.

Paradoxically, poor outcomes have been repeatedly shown to occur in patients without diabetes who develop perioperative hyperglycaemia, compared with patients with diabetes mellitus<sup>5, 19</sup>. Rational therapy is limited by the lack of easy-to deliver glucose monitoring at scale,<sup>1</sup> as well as ongoing controversy over limiting serious side effects of hypoglycaemia frequently associated with exogenous insulin therapy<sup>20, 21</sup>. Postoperative hyperglycaemia may be the most important risk factor for surgical site infections<sup>22</sup>. A Cochrane analysis found insufficient evidence to support strict glycaemic control versus conventional management (maintenance of glucose <10mmol.L-1) for the prevention of surgical site infections<sup>23</sup>. These data are limited by methodological quality, including small sample sizes in single-centre studies plus inconsistencies in glucose measurement and outcome measures. Perioperative hyperglycaemia is also associated with excess myocardial injury<sup>2</sup>. Sustaining subclinical myocardial injury is associated with higher risk of mortality one year after surgery<sup>24</sup>.

Recently, another key study has reported outcomes in 4899 non-diabetic individuals in whom a very high prevalence of blood glucose testing (75%) occurred within 24 hours after surgery<sup>5</sup>. Hyperglycaemia was defined, a priori, as blood glucose level of  $\geq 7.8$ mmol/L within 24 hours after surgery. This study confirmed that patients without diabetes mellitus had worse outcomes than patients with diabetes at similar levels of hyperglycaemia. The authors speculated insulin may mitigate this effect, but this has huge implications for service delivery, patient safety and would require a complete redesign of perioperative glucose monitoring to identify patients who may benefit from treating higher glucose levels. However, the challenges of insulin administration at scale, plus the frequent danger of hypoglycaemia as illustrated by the NICE-SUGAR trial in critically ill patients<sup>20</sup>, suggests that alternative therapies to minimise blood glucose require exploration. Ideally, a real-time monitor to alert clinicians to injurious levels of hyperglycaemia in a non-critical care setting and/or a preoperative test to detect individuals most at risk would rationalise resources. That is now a reality – albeit untested- using continuous (interstitial) glucose monitoring.

#### **4.2. Rationale**

Our aims of the study are to provide detailed data describing the below questions:

1. Measuring intraoperative glucose levels .
2. Examine whether total intravenous anaesthesia (TIVA) reduces postoperative complications (myocardial injury and/or infections) by limiting hyperglycaemia after major noncardiac surgery.
3. Detecting the individual's risk of developing injurious perioperative hyperglycaemia.

#### **4.3. Risks / Benefits**

This trial poses no additional risks as we are comparing two modes of anaesthesia that are part of usual care. Blood samples will be obtained at convenient times to minimise patient inconvenience.

### **5. Study Objectives**

#### **5.1. Primary objective**

To identify association between intraoperative glucose levels and the mode of anaesthesia (TIVA vs inhalational) in patients undergoing major noncardiac surgery.

#### **5.2. Secondary objectives**

- Measure days alive and at home at 30 days (DAH30)
- Establish the interaction between absolute glucose levels and mode of anaesthesia in the perioperative period
- Measure hyperglycaemia profiles in relation to myocardial injury
- Measure hyperglycaemia profiles in relation to postoperative infection
- Can patients with, or susceptible to insulin resistance be identified prior to surgery

#### **5.3. Primary clinical outcome measure**

The primary outcome is blood glucose measurements via:

- Blood-Gas measurements for glucose before surgery, the end of surgery and on day one after surgery.

#### **5.4. Secondary clinical outcome measures**

- DAH30 is a continuous number between 0 and 30, reflecting the total number of days that a patient spends alive and at home within 30 days after surgery. In this definition, home reflects any place other than hospital. If a patient dies within those 30 days, their value is set to 0. DAH30 captures the development of all-cause complications which prevents patients leaving hospital after surgery.
- Increase in serum high sensitivity troponin-T (Elecsys, Roche Diagnostics) concentration of:
  - a. An absolute value of  $\geq 15 \text{ ng L}^{-1}$  on day one after surgery
  - OR
  - b. An increase of  $\geq 5 \text{ ng L}^{-1}$  from the preoperative value on day one after surgery when the preoperative value of  $\geq 15 \text{ ng L}^{-1}$
- Incidence of postoperative infection within 30 days after surgery. This is defined as one or more of the following infections of Clavien-Dindo grade II or greater. A full list of definitions is available in Appendix A:
  - a. Superficial surgical site infection;
  - b. Deep surgical site infection;
  - c. Organ space surgical site infection;
  - d. Pneumonia;
  - e. Urinary tract infection;
  - f. Laboratory confirmed blood stream infection;
  - g. Infection, source uncertain; this is defined as an infection which could be more than one of the above (i.e. a-f), but it is unclear which.
- Continuous glucose measurements using continuous glucose monitoring (CGM) up to 10 days after surgery or hospital discharge whichever is sooner.

### 5.5. Secondary mechanistic laboratory outcome measures

- Plasma C-peptide measurements before surgery and on day one after surgery.
- Insulin measurements before surgery and day one after surgery.
- Flow cytometry assessment of metabolic dependence of leukocytes before surgery, the end of surgery, day one after surgery and on day of hospital discharge.\*

*\* This will only be done at selected sites.*

## **6. Study Design**

### **6.1. Study setting**

National, multi-centre randomised trial.

### **6.2. Inclusion criteria**

- Aged  $\geq 50$  years
- Elective major noncardiac surgery under general anaesthesia (as per PQIP inclusion criteria)
- Written informed consent for trial participation

### **6.3. Exclusion criteria**

- Known contraindication to either TIVA or inhalational anaesthesia
- Clinical refusal
- Procedures where the participant is not expected to survive for 30 days
- Previous participating and completion in the GlucoVITAL trial
- Patient unable to give informed consent or complete questionnaires

## **7. Study Procedures**

### **7.1. Participant identification**

During the trial recruitment period, hospital research teams will liaise with clinical staff to identify individuals with upcoming major noncardiac surgery that may be eligible for enrolment. Based on this referral, a member of the team delivering the trial at the hospital (e.g. clinician, nurse or research practitioner) with appropriate knowledge will formally assess eligibility of the participant against trial inclusion and exclusion criteria. No additional tests or investigations will be required for assessing eligibility.

### **7.2. Informed consent considerations**

Potential participants will be screened by research staff at the site having been identified from pre-admission clinic lists, operating theatre lists and by communication with the relevant nursing and medical staff. Before surgery, potential participants will be identified and approached by a member of the research team, who are considered part of the direct care team. This may be conducted via telephone, post, online or face-to-face consultations and provides an opportunity for the research team to explain the trial to the participants in detail. Patient information sheets can be posted or emailed

to participants for their perusal and consideration. The participant will be approached prior to surgery at the first suitable opportunity to allow time for any questions. It is recommended (although not mandated) that the participant is approached at least one day prior to the date of surgery. Written informed consent must be obtained before surgery and can be obtained using either paper or electronic systems depending on individual sites arrangements. It is the responsibility of the Principal Investigator (PI) at each site, or persons delegated by the PI to obtain written informed consent from each potential participant prior to participation in this trial. This process will include provision of a patient information sheet accompanied by the relevant consent form, either paper or electronic, and an explanation of the aims, methods, anticipated benefits and potential hazards of the trial. The PI or designee will explain to all potential participants that they are free to refuse to enter the trial or to withdraw at any time during the trial, for any reason. If new safety information results in significant changes in the risk/benefit assessment, the patient information sheet and consent form will be reviewed and updated if necessary. The PI or designee will assess potential participant's capacity to give informed consent, and those who lack capacity to give or withhold informed consent will not be recruited. If a participant loses capacity during their participation in the trial, the original consent by the participant will be respected. If this situation occurs, clinical outcome data will continue to be collected, but participant questionnaires will not need to be completed. Patients who are not entered into this trial should be recorded (including reason not entered) on the electronic patient-screening log provided to sites in the Investigator Site File.

### **7.3. Randomisation**

Participants will be randomised on a 1:1 basis to receive either TIVA or inhalational anaesthesia by a computer generated procedure. This computerised procedure will use a minimisation algorithm to ensure balance in treatment arm allocation across the following four stratification variables, factors thought to affect outcome either through treatment effectiveness or underlying prognosis, also permitting appropriate exploratory subgroup analyses:

- 1) Surgical speciality (musculoskeletal/intra-abdominal/thoracic/vascular/other)
- 2) Expected duration of surgery (<2hours, ≥2hours)
- 3) Cancer surgery/non-cancer surgery
- 4) Preoperative frailty (Rockwood Frailty Score) - Well/Vulnerable/Frail<sup>25</sup>

### **7.4. Randomising on the day of surgery**

Recruiting centres will be asked to randomise participants on the day of surgery, once the planned surgery is confirmed as taking place. There will be occasions when surgery is cancelled at the last minute and rescheduled to another day. If the participant is happy to remain in the trial, recruiting centres will be asked to inform the GlucoVITAL team of the new surgery date as soon as possible, and data collection timepoints will be adjusted. Participants should receive their original allocated intervention at their new scheduled surgery date. If the surgery is cancelled indefinitely, or the participant is no longer suitable for the trial, the recruiting centre will be asked to inform the GlucoVITAL team as soon as possible.

## **7.5. Trial intervention**

Anaesthesia will be administered by experienced anaesthetists and delivered according to local guidelines. All other participant care will be conducted as per routine clinical practice. More detailed information regarding trial intervention will be provided to sites as part of the trial-specific training.

### **7.5.1. Total Intravenous Anaesthesia (TIVA)**

Participants randomised to the TIVA arm of the trial will have their maintenance of anaesthesia performed with intravenous anaesthetic agents as determined by the treating anaesthetist. Administration of TIVA will not be protocolised and will be left to clinical discretion for management. Maintenance of general anaesthesia should be via TIVA only. During training, it will be emphasised that clinicians should not expose TIVA group participants to inhaled anaesthetic agents.

### **7.5.2. Volatile-based Inhalational Anaesthesia (INH)**

Participants randomised to the INH arm of the trial will have their maintenance of anaesthesia performed with inhalational volatile-based anaesthetic agents as determined by the treating anaesthetist. Administration of INH will not be protocolised and will be left to clinical discretion for management. Maintenance of general anaesthesia should be via inhalational route only. During training, it will be emphasised that clinicians should not expose INH group participants to intravenous anaesthetic agents.

## **7.6. Glucose measurements**

Glucose will be measured using:

- Blood-gas measurements recorded on:

- Day of surgery before induction of anaesthesia
  - End of surgery defined as the patient leaving the operating room (+ 2 hours)
  - Day one after surgery (10:00am  $\pm$  6 hours)
- 
- Continuous glucose monitoring Dexcom G7 patches and sensor. The patient will wear these monitors continuously from induction of anaesthesia up to 10 days postoperatively [maximum usage duration for each sensor] or hospital discharge whichever occurs sooner. The glucose monitor will be provided by the Sponsor.

### 7.7. Assessment of outcome measures

Blood samples (approximately 15 ml) will be collected to measure:

- Myocardial injury: Plasma high sensitivity troponin-T (Elecsys, Roche Diagnostics) levels will be measured in blood samples collected on the day of surgery before the induction of anaesthesia and on day one after surgery (10:00am  $\pm$  6 hours).
- Presence and/or development of insulin resistance: Plasma C-peptide and insulin levels (ELISA assays) will be measured on the day of surgery before the induction of anaesthesia and on day one after surgery (10:00am  $\pm$  6 hours).
- Leukocyte and metabolic profiles: Whole blood will be analysed by flow cytometry on the day of surgery before the induction of anaesthesia, within 2 hours after the end of surgery (defined as time at which surgical drapes are removed), day one after surgery (10:00am  $\pm$  6 hours) and day of hospital discharge (10:00am  $\pm$  6 hours).

Participants will be contacted by telephone at day 30 (+ 2 days) by site research staff to collect data on hospital readmission and any postoperative complications that classed as Clavien-Dindo Severity Grade II or above (Appendix A). When assessing the Clavien-Dindo complications, if the initial assessment will be made by a research associate; this will typically be a research nurse but may include physicians and surgeons. This initial assessment by the research associate will be based on clinical information including information from patients' medical notes, including (but not limited to) microbiology test results, blood test results, drug prescription charts, radiology tests etc. Patients discharged from hospital before day 30 will be contacted shortly after day 30 to ascertain whether they have received any new treatment since discharge, or if they have been re-admitted to hospital or seen a doctor since discharge. For patients

who have received further treatment or seen a health professional since discharge, further details will be collected directly from the hospital/doctor or from the patient's health records to be used in the research associate's assessment. If the initial assessment by the research associate is of 'no infection', then the patient's outcome is classified as 'no infection'. If the initial assessment is of 'infection', then this decision must be confirmed by the site Principal Investigator (PI), who will evaluate the information used by the research associate in their initial assessment. The PI's decision is final; they can either confirm the research associate's initial assessment of 'infection' (in which case the patient's outcome is classified as 'infection'), or they can refute it (in which case the patient's outcome is classified as 'no infection').

## 7.8. Schedule of study intervention

Visit	1	2	3	4	5	6
Visit Window	Day 0 pre-op	Day 0 post-op	Day 1 <sup>#</sup> post-op	Day 2- Day10 post-op	Day of hospital discharge <sup>#</sup>	Day 30 + 7 days
Informed consent	x					
Medical history	x					
Inclusion/exclusion criteria	x					
Surgical speciality	x					
Expected duration of surgery (<2hrs, ≥2hrs)	x					
Cancer surgery/non-cancer surgery	x					
Preoperative frailty (Rockwood Frailty Score)	x					
Collection of trial blood sample	x	x	x		x	
Blood gas glucose measurement	x	x	x			
Real time continuous glucose monitoring	x	x	x	x		
Post-operative complications (Clavien-Dindo Grade II and above)						x
Length of stay*					x	
Survival status*						x
Hospital readmission*						x

<sup>#</sup> Or closest next working day

## 7.9. Written/ reading / translation considerations

The research team will not recruit participants unless the patient information sheet, consent form and video are provided in the appropriate language.

## 7.10. Withdrawals

Participants may withdraw from trial at any time without prejudice. Data will be collected as per the trial protocol unless the participant has explicitly withdrawn their consent.

## 7.11. End of trial definition

The end of the trial (EOT) is defined as 180 days from the when the last patient had completed their 30 day follow-up.

## **8. Laboratories and samples**

### **8.1. Central laboratories**

Myocardial injury will be assessed based on plasma high sensitivity troponin-T (Elecsys, Roche Diagnostics) and the analysis will be conducted by The Doctor's Laboratory.

### **8.2. Local laboratories**

C-peptide analysis and insulin resistance will be measured on plasma samples (ELISA, ABCAM) and the analysis will be conducted by the Chief Investigator in the Translational Medicine and Therapeutics laboratory, William Harvey Research Institute (WHRI).

### **8.3. Sample collection and labelling logging**

All blood samples will be pseudo-anonymised. Samples collected at each participating site will be labelled with the participant's corresponding study ID and kept in a hospital freezer at an optimal temperature for the troponin assay until collection. The samples will be routinely collected and transferred to WHRI where they will be stored prior to transfer to The Doctor's Laboratory for analysis. The full sample, collection, labelling, logging and transfer procedure will be documented in the trial laboratory log.

### **8.4. Sample receipt/chain of custody/accountability**

Handling of the samples upon arrival at the local and central laboratory will be documented. All samples will be logged upon receipt and the laboratory will ensure that the integrity of these samples have not been compromised in transit. If compromise has occurred, the trial coordinating team, as well as the Sponsor, will be informed of this. Upon receipt of samples, laboratory staff will ensure that all samples are accounted for as per the labelling.

### **8.5. Sample storage procedures**

The samples should be put in the freezer within two hours of blood samples being collected from the patient. The samples will not be destroyed if a patient withdraws from the study unless they specifically request so. If the patient requests for the samples to be destroyed the Tissue Custodian (Chief Investigator), will inform the lab

who will ensure the samples are destructed as per the Human Tissue Act. This will be documented in the Trial Master File and Investigator Site File of the participating site.

#### **8.6. Sample and data recording/reporting**

Troponin-T data will be measured by the central laboratory and shared by secure electronic communication after the last patient sample has been analysed.

#### **8.7. End of study**

The samples will be stored beyond the end of the trial to be used for closely related studies in the future. After completion of any potential sub-studies the samples will be destroyed according to the Human Tissue Authority's Code of Practice.

### **9. Safety reporting**

#### **9.1. Definitions**

##### **9.1.1 Adverse Events (AE)**

An Adverse Event (AE) is defined as any untoward medical occurrence in a trial participant, and which does not necessarily have a causal relationship with the treatment/intervention.

##### **9.1.2 Serious Adverse Events (SAEs)**

A Serious Adverse Event is an AE that fulfils one or more of the following criteria:

- Results in death
- Is immediately life-threatening
- Requires hospitalisation or prolongation of existing hospitalisation
- Results in persistent or significant disability or incapacity
- Is a congenital abnormality or birth defect
- Immediate intervention was required to prevent one of the above or is an important medical condition.

#### **9.2 Site investigator assessment**

The Principal Investigator is responsible for the care of the participant, or in their absence an authorised medic within the research team is responsible for assessment of any event for:

- Seriousness: Assessing whether the event is serious according to the definitions given in section 9.1.

- Causality: Assessing the causality of all serious adverse events in relation to the study treatment according to the definition given. If the SAE is assessed as having a reasonable causal relationship with the investigational device, then it is defined as an ADE.
- Expectedness: Assessing the expectedness of all ADEs according to the definition given. If the ADE is unexpected (as per the risk analysis or other RSI document), then it is a USADE.
- Severity: Assessing the severity of the event according to the following terms and assessments. The intensity of an event should not be confused with the term “serious” which is a regulatory definition based on participant/event endpoint criteria.
  - o Mild: Some discomfort noted but without disruption of daily life
  - o Moderate: Discomfort enough to affect/reduce normal activity
  - o Severe: Complete inability to perform daily activities and lead a normal life

It is expected that patients undergoing major abdominal surgery will suffer medical complications, with consequences up to and including death. **Only complications considered by the Chief Investigator to be related to the use of study procedures and not a typical complication of surgery should be reported as SAEs.**

### 9.2.1 Notification and reporting of Serious Adverse Events

Serious Adverse Event (SAEs) that are considered to be ‘related’ and ‘unexpected’ are to be reported to the sponsor and the sponsor’s representative for that country within 72 hours of learning of the event.

### 9.2.2 Reporting a Serious Adverse Events

Individual sites will notify the co-ordinating centre in that country of an SAE by emailing a scanned copy of the supplementary SAE report form to the national coordinator. SAEs will be reported within 72 hours and will be forwarded to the sponsor via the UK co-ordinating centre.

## 10. Statistical considerations

A detailed statistical analysis plan will be drafted by the trial statistician, which will be finalised and approved by the CI and an independent statistician before the final data

analysis. All statistical analyses will be undertaken on an intention to treat basis to preserve randomisation, avoid bias from exclusions and preserve statistical power. Hence all participants enrolled into the study, regardless of whether they received their randomised intervention, will be analysed according to their randomised group using data collected up to their 30-day time-point, or the last time-point prior to their withdrawal or loss to follow-up before this. Patients not receiving surgery or withdrawing consent for follow-up prior to surgery will not be included in relevant denominators.

For the primary outcome of blood glucose change from the start of surgery until the end of surgery, each randomised treatment arm's point estimates (and 95% confidence interval) will be reported. In addition, blood glucose measurements from the start of surgery until the end of surgery will be compared across randomised treatment arms using independent samples t-tests, or Wilcoxon rank sum tests depending on the distribution of the data. The secondary clinical outcomes (incidence of myocardial injury and/or all-cause infection) will be assessed across trial arms using a chi-squared test. The continuous variables measuring mechanistic outcomes of glucose and metabolic profiles will initially be compared across trial arms using independent samples t-tests, or Wilcoxon rank sum tests (depending on the distribution of the data). Further comparisons across trial arms of blood glucose measures over time and the mechanistic outcomes over time will use repeated measures analyses, a statistically efficient approach that allows all of the follow-up data collated during the study to be used.

For GlucoVITAL, four factors define sub-groups of interest: (1) Surgical speciality (intraabdominal/other); (2) Cancer surgery/non-cancer surgery; (3) Incidence of hyperglycaemia (glucose  $<7.8$ mmol/L) within first 24h of surgery (including at time of induction of anaesthesia); (4) Diabetes mellitus/no diabetes mellitus. Pre-specified sub-group analyses that will be undertaken using appropriate modelling techniques. These will be determined following examination of the distributions of the collected data. These exploratory sub-group analyses will have lower power than the main whole trial analysis but are hypothesis-generating and results will be scrutinised graphically via forest plots.

Descriptive statistics will be used to summarise the distribution of baseline variables across each of the randomisation arms. Continuous variables will be reported with

means and 95% confidence intervals, if normally distributed, or medians and Interquartile Ranges (IQR) otherwise. Categorical variables will be reported using frequencies and percentages.

A Consolidated Standards of Reporting Trials (CONSORT) flow diagram will be produced, showing the frequency of participants:

- Assessed for eligibility
- Excluded prior to randomisation (and the frequency of each reason for exclusion)
- Allocated to each randomisation arm
- Receiving or not receiving their randomised treatment
- Followed-up at each protocol specified timepoints
- Lost to follow-up at each protocol specified timepoints (plus frequency of each reason for loss to follow-up)

### **10.1. Sample size**

The primary outcome is intraoperative blood glucose. From current VITAL data, mean blood glucose in 47 non-diabetic patients increased by 2.2mmol/L (SD:1.8) at the end of surgery. Assuming 5% 2-sided significance and 90% power, with a SD of glucose change by the end of surgery of up to 1.8mmol/L, at least 390 patients are required to detect a difference of 0.6mmol/L in glucose increases between modes of anaesthesia (allowing for nominal 2% dropout).

For the secondary (composite) clinical outcome: ~47% OPTIMISE/VISION-UK participants >50y sustain myocardial injury within the first 24 hours after surgery (~48%) and/or all-cause infection at any time before hospital discharge (~20% participants). With 450 patients recruited, we will have a 90% chance of detecting (at 5% 2-sided significance), a decrease in this composite outcome from 56% with inhalational versus 40% with intravenous anaesthesia (allowing for a 4% drop out). We will also record DAH30, which reflects composite complications after surgery.

For the secondary mechanistic outcomes: glucose and metabolic profiles after surgery in each anaesthetic group will be quantified by:

- 1) Continuous glucose monitoring: complications are twice as likely when blood glucose is >7.8mmol/L within 24 hours after surgery, which occurs in ~50% individuals without previous diabetes<sup>5</sup>. We will therefore examine the

interaction between blood glucose levels in the range of 3.9-7.8mmol/L within 24 hours of surgery, interstitial glucose variability<sup>26</sup> and anaesthetic type with secondary outcomes. Time in range will be defined as % total time within glucose range 3.9-7.8mmol/L within 24 hours of surgery, and for the duration of sensor measurements (maximum 10 days, or hospital stay <10 days).

- 2) Insulin resistance: The Homeostatic Model Assessment for Insulin Resistance (HOMAIR) will be used to estimate insulin resistance. Paired fasting plasma glucose and C-peptide will be quantified by lab personnel blinded to clinical/glucose data. Based on previous work examining the effect of methylprednisolone on insulin resistance<sup>44</sup>, 45 patients per arm are required to have a 90% chance of detecting (5% 2-sided significance) a difference of 1 SD (0.6) in HOMA-IR between intravenous and inhalational anaesthesia 24 hours after surgery (2% dropout).
- 3) Flow cytometry quantification of leukocytes, based on our previous data on glutamine dependence of T cells. Samples will be analysed before induction of anaesthesia, end of surgery and day one after surgery. Assuming 5% 2-sided significance, SD of glutamine dependence of up to 7% and 90% power, 133 patients are required to detect a difference of 4% in glutamine dependence between modes of anaesthesia (allowing for nominal 2% dropout).

## 11. Ethics

The CI must ensure that the study is conducted in accordance with the guidelines of the International Conference on Harmonisation, Good Clinical Practice (GCP) and UK legislation. All study documentation will be reviewed and approved by the research ethics committee prior to start of recruitment. Research Ethics Committee, Health Research Authority and Sponsor approvals will be in place before patient recruitment commences. The study will be sponsored by QMUL. Additionally, each participating site will ensure that the approval of the relevant trust Research & Development department and Ethics Committee is in place and a written confirmation is provided to the Sponsor.

### **11.1. Annual Safety Reporting**

The CI will send the annual progress report to the REC and Sponsor using the anniversary of the REC 'favourable opinion'.

## **12. Public Involvement**

The grant proposal for this study has been designed with the PPI members at The Patient, Carer & Public Involvement and Engagement (PCPIE) group (support (<https://www.niaa-hsrc.org.uk/PCPIE>)). Furthermore, our PPI co-applicant have reviewed the protocol and will continue to advise us for the duration of the study including dissemination of the study results. Patient research partners will review the protocol and patient-facing documents to ensure that they are fit for purpose and refine our consenting procedures. They will join our regular Trial Management Committee meetings and review participant recruitment progress.

## **13. Data Handling and Record Keeping**

### **13.1. Information governance**

The study will be sponsored by Queen Mary University of London and will follow NHS and sponsor standard operating procedures for data storage and access and are consistent with the principles of the Data Protection Act and General Data Protection Regulation (GDPR).

### **13.2. Data management**

Data will be transcribed onto the electronic CRF (eCRF) on the secure data entry web portal. Submitted data will be reviewed for completeness and consistency by authorised users within the trial coordinating team. Submitted data will be stored in Queen Mary University of London safe haven securely against unauthorised manipulation and accidental loss. Only authorised users at site, or at Barts Health NHS Trust will have access. Desktop security is maintained through usernames and passwords. Data back-up procedures are in place and a full audit trail will be kept. Storage and handling of confidential trial data and documents will be in accordance with the Data Protection Act 2018 (UK).

### **13.3. Source Data**

The eCRF will count as source data for patient reported outcomes collected during the 30-day follow-up. Patients' medical notes will act as source for the rest of the data. It is expected that the exact source data list will vary by site.

#### **13.4. Confidentiality**

The PI has a responsibility to ensure that participant anonymity is protected and maintained. They must also ensure that their identities are protected from any unauthorised parties. The Sponsor will ensure that all participating partner organisations will maintain the confidentiality of all subject data and will not reproduce or disclose any information by which subjects could be identified, other than reporting of serious adverse events. In the case of special problems and/or competent authority queries, it is also necessary to have access to the complete trial records, provided that patient confidentiality is protected. Information with regards to study participants will be kept confidential and managed in accordance with the Data Protection Act, NHS Caldicott Guardian, The Research Governance Framework for Health and Social Care and Research Ethics Committee Approval. The Chief Investigator and the study team will adhere to these parameters to ensure that the participant's identity is protected at every stage of their participation within the study. Patients will be anonymised with regards to any publications relating to this study.

#### **13.5. Record retention and archiving**

During the course of research, the CI has full responsibility of all study records which must be kept in secure conditions at all times. The UK Policy Framework for Health and Social Care Research and Sponsor SOP, requires that research records are kept for 20 years after the study has completed. Archiving will be authorised by the Sponsor following submission of the end of study report. The Sponsor is responsible for maintaining and archiving the study TMF. The study database will be stored according to the Sponsor's policies. Electronic data sets will be stored indefinitely. The sites are responsible for maintaining and archiving all local records including the ISF and CRFs. These records should be archived together once authorisation has been given by the Sponsor. It is the responsibility of the PI to ensure a full set of records is collated and documented.

#### **13.6. Monitoring and Auditing**

The Sponsor or delegate retains the right to audit any study, study site or central facility. In addition, any part of the study may be audited by the funders where

applicable. The GlucoVITAL study master documents may be audited by the Sponsor to ensure study activities are conducted according to the protocol, the Sponsor's standard operating procedures, GCP and the applicable regulatory requirements. In participating hospitals, local study documents may be selected for audit on a local basis. However, the GlucoVITAL study team will not routinely monitor data collection in individual hospitals or conduct source data verification.

## **14. Trial Management & Committees**

### **14.1. Trial management group**

Day-to-day management will be co-ordinated by the Critical Care and Perioperative Medicine Research Group (CCPMG) based at Queen Mary University of London. The day-to-day conduct of the study trial will be led by the trial management group, under the management of the CI(s) or nominated deputy.

### **14.2. Trial steering committee (TSC)**

The TSC will be periodically reviewing safety data, blind to the randomised arm, and liaising with the DMC regarding safety issues.

### **14.3. Data Monitoring Committee (DMC)**

The DMC, periodically reviewing safety data, split by randomised arm, to determine patterns and trends of events, identifying safety issues which would not be apparent on an individual case basis.

## **15. Finance and Funding**

The GlucoVITAL study is funded by the Efficacy and Mechanism Evaluation (EME) Programme awarded to the CI. The funders will play no role in study design, conduct, data collection, data analysis, reporting or interpretation of the results.

## **16. Sponsorship and Insurance**

The insurance that Queen Mary University of London has in place provides cover for the design and management of the study as well as "No Fault Compensation" for participants, which provides an indemnity to participants for negligent and non-negligent harm.

## **17. Dissemination of Research Findings**

Data arising from this research will be made available to the scientific community in a timely and responsible manner. A detailed scientific report will be submitted to a widely accessible scientific journal on behalf of the GlucoVITAL study group. At least one of the lay members will contribute to the dissemination of protocol and final manuscripts. Authorship of the final manuscript(s), interim publications, or abstracts will be decided according to active participation in the design, committee membership, accrual of eligible patients and statistical analysis. All authors will comply with internationally agreed requirements for authorship and will approve the final manuscript prior to submission. The funders, contributing centres (and participating investigators) will be acknowledged in the final manuscript. No investigator may present data from his/her centre separately from the rest of the study results unless approved by the study management team and the Sponsor. The full study report will be submitted to the funder and will also be made accessible via ISRCTN.



## 18. References

- 1 Duggan EW, Carlson K, Umpierrez GE. Perioperative Hyperglycemia Management: An Update. *Anesthesiology* 2017; 126: 547-60
- 2 Punthakee Z, Iglesias PP, Alonso-Coello P, et al. Association of preoperative glucose concentration with myocardial injury and death after non-cardiac surgery (GlucoVISION): a prospective cohort study. *Lancet Diabetes Endocrinol* 2018; 6: 790-7
- 3 Kwon S, Thompson R, Dellinger P, Yanez D, Farrohi E, Flum D. Importance of perioperative glycemic control in general surgery: a report from the Surgical Care and Outcomes Assessment Program. *Ann Surg* 2013; 257: 8-14
- 4 Khuri SF, Henderson WG, DePalma RG, Mosca C, Healey NA, Kumbhani DJ. Determinants of long-term survival after major surgery and the adverse effect of postoperative complications. *Ann Surg* 2005; 242: 326-41
- 5 Chen JY, Nassereldine H, Cook SB, Thornblade LW, Dellinger EP, Flum DR. Paradoxical Association of Hyperglycemia and Surgical Complications Among Patients With and Without Diabetes. *JAMA Surg* 2022
- 6 Esposito K, Nappo F, Marfella R, et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. *Circulation* 2002; 106: 2067-72
- 7 Fowler AJ, Dobbs TD, Wan YI, et al. Resource requirements for reintroducing elective surgery during the COVID-19 pandemic: modelling study. *Br J Surg* 2021; 108: 97-103
- 8 Dungan KM, Braithwaite SS, Preiser JC. Stress hyperglycaemia. *Lancet* 2009; 373: 1798-807
- 9 Collaborators GBDRF. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* 2018; 392: 1923-94
- 10 Anderson EJ, Lustig ME, Boyle KE, et al. Mitochondrial H<sub>2</sub>O<sub>2</sub> emission and cellular redox state link excess fat intake to insulin resistance in both rodents and humans. *J Clin Invest* 2009; 119: 573-81
- 11 Rueggsegger GN, Creo AL, Cortes TM, Dasari S, Nair KS. Altered mitochondrial function in insulin-deficient and insulin-resistant states. *J Clin Invest* 2018; 128: 3671-81
- 12 Edwards MR, Sultan P, del Arroyo AG, et al. Metabolic dysfunction in lymphocytes promotes postoperative morbidity. *Clin Sci (Lond)* 2015; 129: 423-37
- 13 Sena LA, Li S, Jairaman A, et al. Mitochondria are required for antigen-specific T cell activation through reactive oxygen species signaling. *Immunity* 2013; 38: 225-36
- 14 Kim KD, Zhao J, Auh S, et al. Adaptive immune cells temper initial innate responses. *Nat Med* 2007; 13: 1248-52
- 15 Macaulay R, Akbar AN, Henson SM. The role of the T cell in age-related inflammation. *Age (Dordr)* 2013; 35: 563-72
- 16 Warny M, Helby J, Nordestgaard BG, Birgens H, Bojesen SE. Lymphopenia and risk of infection and infection-related death in 98,344 individuals from a prospective Danish population-based study. *PLoS Med* 2018; 15: e1002685
- 17 D'Alessio FR, Kurzban JT, Rabb H. Reparative T lymphocytes in organ injury. *J Clin Invest* 2019; 129: 2608-18
- 18 Schroth J, Weber V, Jones TF, Del Arroyo AG, Henson SM, Ackland GL. Preoperative lymphopaenia, mortality, and morbidity after elective surgery: systematic review and meta-analysis. *Br J Anaesth* 2021; 127: 32-40
- 19 Frisch A, Chandra P, Smiley D, et al. Prevalence and clinical outcome of hyperglycemia in the perioperative period in noncardiac surgery. *Diabetes Care* 2010; 33: 1783-8
- 20 Investigators N-SS, Finfer S, Chittock DR, et al. Intensive versus conventional glucose control in critically ill patients. *N Engl J Med* 2009; 360: 1283-97
- 21 Bohe J, Abidi H, Brunot V, et al. Individualised versus conventional glucose control in critically-ill patients: the CONTROLLING study-a randomized clinical trial. *Intensive Care Med* 2021; 47: 1271-83
- 22 Ata A, Lee J, Bestle SL, Desemone J, Stain SC. Postoperative hyperglycemia and surgical site infection in general surgery patients. *Arch Surg* 2010; 145: 858-64
- 23 Kao LS, Meeks D, Moyer VA, Lally KP. Peri-operative glycaemic control regimens for preventing surgical site infections in adults. *Cochrane Database Syst Rev* 2009: CD006806

- 24 Writing Committee for the VSI, Devereaux PJ, Bickard BM, et al. Association of Postoperative High-Sensitivity Troponin Levels With Myocardial Injury and 30-Day Mortality Among Patients Undergoing Noncardiac Surgery. *JAMA* 2017; 317: 1642-51
- 25 Rockwood K, Song X, MacKnight C, et al. A global clinical measure of fitness and frailty in elderly people. *CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne* 2005; 173: 489-95
- 26 Phillips NE, Collet TH, Naef F. Uncovering personalized glucose responses and circadian rhythms from multiple wearable biosensors with Bayesian dynamical modeling. *Cell Rep Methods* 2023; 3: 100545

## 19. Appendices

### 19.1. Appendix A

#### *Definitions of infections Surgical site infection (superficial surgical site)*

An infection at the surgical incision site which meets the following criteria:

- Involves only skin and sub-cutaneous tissue of the incision and
- The patient has at least one of the following:
  - purulent drainage from the superficial incision
  - organisms isolated from an aseptically obtained culture of fluid or tissue from the superficial incision
  - at least one of the following symptoms or signs of infection: pain or tenderness, localized swelling, redness, or heat, and superficial incision is deliberately opened by surgeon and is culture positive or not cultured. A culture-negative finding does not meet this criterion.
  - diagnosis of an incisional surgical site infection by a surgeon or attending physician

#### *Surgical site infection (deep surgical site)*

An infection at the surgical incision site which meets the following criteria:

- Involves deep soft tissues (e.g. fascial and muscle layers) of the incision and
- The patient has at least one of the following:
  - purulent drainage from the deep incision but not from the organ/space component of the surgical site
  - a deep incision spontaneously dehisces or is deliberately opened by a surgeon and is culture-positive or not cultured when the patient has at least one of the following symptoms or signs: fever ( $>38^{\circ}\text{C}$ ), or localized pain or tenderness. A culture-negative finding does not meet this criterion.
  - an abscess or other evidence of infection involving the deep incision is found on direct examination, during surgery, or by histopathologic or radiologic examination
  - diagnosis of an incisional surgical site infection by a surgeon or attending physician

#### *Surgical site infection (organ/space)*

An infection at the surgical incision site, excluding the fascia or muscle layers, which appears to be related to the surgical procedure and involves any part of the body, excluding the skin incision, fascia, or muscle layers, that is opened or manipulated during the operative procedure and the patient has at least one of the following:

- purulent drainage from a drain that is placed through a stab wound into the organ/space

- organisms isolated from an aseptically obtained culture of fluid or tissue in the organ/space
- an abscess or other evidence of infection involving the organ/space that is found on direct examination, during reoperation, or by histopathologic or radiologic examination
- diagnosis of an organ/space surgical site infection by a surgeon or attending physician

### *Pneumonia*

This is defined as two or more serial chest radiographs with at least one of the following (one radiograph is sufficient for patients with no underlying pulmonary or cardiac disease):

- a) new or progressive and persistent infiltrates
- b) consolidation
- c) cavitation

And at least one of the following:

- a) fever ( $>38^{\circ}\text{C}$ ) with no other recognized cause
- b) leucopenia ( $12,000 \text{ cells/mm}^3$ )
- c) for adults  $>70$  years old, altered mental status with no other recognized cause

And at least two of the following:

- a) new onset of purulent sputum or change in character of sputum, or increased respiratory secretions, or increased suctioning requirements
- b) new onset or worsening cough, or dyspnoea, or tachypnoea
- c) rales or bronchial breath sounds
- d) worsening gas exchange (hypoxia, increased oxygen requirement, increased ventilator demand)

### *Urinary tract infection*

A positive urine culture of  $\geq 10^5$  colony forming units/mL with no more than two species of micro-organisms with at least one of the following symptoms or signs: fever ( $>38^{\circ}\text{C}$ ), urgency, frequency, dysuria, supra-pubic tenderness, costo-vertebral angle pain or tenderness with no other recognised cause, identified within a 24-hour period.

Alternatively, the patient has an abscess or other evidence of infection seen on direct examination, during a surgical operation, or during a histopathologic examination with one of the following:

- a) purulent drainage from affected site;
- b) radiographic evidence of infection;

c) physician diagnosis of infection of the kidney, ureter, bladder, urethra, or tissues surrounding the retroperitoneal or perinephric space; d) physician institutes antibiotic therapy for an infection of the kidney, ureter, bladder, urethra, or surrounding tissues.

*Laboratory confirmed bloodstream infection*

An infection which meets at least one of the following criteria but is not related to infection at another site:

- Patient has a recognised pathogen cultured from one or more blood cultures and the organism cultured from blood is not related to an infection at another site
- Patient has at least one of the following signs or symptoms: fever ( $>38^{\circ}\text{C}$ ), chills, or hypotension and at least one of the following:
  - a) common skin contaminant cultured from two or more blood cultures drawn on separate occasions
  - b) common skin contaminant cultured from at least one blood culture from a patient with an intravascular line, and the physician institutes antimicrobial therapy
  - c) positive blood antigen test

*Infection, source uncertain*

An infection which is considered likely to be one of the following but cannot be differentiated because clinical information suggests more than one possible site: Superficial surgical site infection, or Deep surgical site infection, or Organ space surgical site infection, or Pneumonia, or Urinary tract infection, or Laboratory confirmed blood stream infection. There must be a strong clinical suspicion of infection meeting two or more of the following criteria:

1. Core temperature  $38^{\circ}\text{C}$
2. White cell count  $>12 \times 10^9/\text{L}$  or  $<4 \times 10^9/\text{L}$
3. Respiratory rate  $>20$  breaths per minute or  $\text{PaCO}_2 <35 \text{ mmHg}$
4. Pulse rate  $>90$  beats per minute